Tuesday, July 15, 2025 11:18:32 AM
“I am at a loss though why any interested company hasn't provided additional funds to nwbo to continue to operate or if there is a limit of shares allowed on the market before B/O?”
— the better question to ask is why has LP been diluting in .20s over the last several months, if a deal post approval was pretty much inked (whether that be a partnership (licensing with upfront cash) or a buyout offer). She would be able to negotiate from a position of strength. As a fund, I would want in on a 5 to 10X return in less than an year. Who wouldn’t? More importantly, she would have initiated a loan rather than diluting $17M+ shares at .22 just a week or two ago, if a big cash windfall was coming in the next few months. Tells you everything you need to know.
If you don’t live in denial, it becomes evident that LP has nothing meaningful up her sleeve. That’s why there is no support from the market because everyone expects LP to continue to dilute endlessly for years to come with share price dropping to all low time lows and continue making new all time lows moving forward. The only thing that won’t stop is excuses and kicking of can. Thats been the consistent pattern for the last 15 years!
Expect a request to raise the authorized share count in the coming months.
By the way, what happened to that $50M financing arrangement. Did they exhaust it in the first half of this year?
— the better question to ask is why has LP been diluting in .20s over the last several months, if a deal post approval was pretty much inked (whether that be a partnership (licensing with upfront cash) or a buyout offer). She would be able to negotiate from a position of strength. As a fund, I would want in on a 5 to 10X return in less than an year. Who wouldn’t? More importantly, she would have initiated a loan rather than diluting $17M+ shares at .22 just a week or two ago, if a big cash windfall was coming in the next few months. Tells you everything you need to know.
If you don’t live in denial, it becomes evident that LP has nothing meaningful up her sleeve. That’s why there is no support from the market because everyone expects LP to continue to dilute endlessly for years to come with share price dropping to all low time lows and continue making new all time lows moving forward. The only thing that won’t stop is excuses and kicking of can. Thats been the consistent pattern for the last 15 years!
Expect a request to raise the authorized share count in the coming months.
By the way, what happened to that $50M financing arrangement. Did they exhaust it in the first half of this year?
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
